Completion of the Divestment of Aspen’s European Thrombosis Business to Mylan

ASPEN PHARMACARE HOLDINGS LIMITED
(Incorporated in the Republic of South Africa) (“Aspen Holdings”)
Registration number: 1985/002935/06
Share code: APN
ISIN: ZAE000066692
LEI: 635400ZYSN1IRD5QWQ94
and its subsidiaries (collectively “Aspen” or “the Group”)


COMPLETION OF THE DIVESTMENT OF ASPEN’S EUROPEAN THROMBOSIS BUSINESS TO MYLAN


Shareholders are referred to the announcement of 8 September 2020 wherein it was confirmed that Aspen
Global Incorporated, incorporated in Mauritius, a wholly owned subsidiary of Aspen Holdings, had
concluded an agreement in terms whereof Mylan Ireland Limited would acquire the commercialisation
rights and related intellectual property in respect of Aspen’s Thrombosis Business in Europe(1)(the
“Transaction”).

Aspen is pleased to confirm that it has received confirmation that all conditions precedent for the
Transaction have now been fulfilled and that the Transaction closed on 27 November 2020.

Footnote:
(1)Excludes Russia and the other Commonwealth of Independent States countries.


Durban
02 December 2020

Sponsor
Investec Bank Limited




Date: 02-12-2020 09:00:00

Supplied by www.sharenet.co.za
Produced by the JSE SENS Department. The SENS service is an information dissemination service administered by the JSE Limited ('JSE'). 
The JSE does not, whether expressly, tacitly or implicitly, represent, warrant or in any way guarantee the truth, accuracy or completeness of
 the information published on SENS. The JSE, their officers, employees and agents accept no liability for (or in respect of) any direct, 
indirect, incidental or consequential loss or damage of any kind or nature, howsoever arising, from the use of SENS or the use of, or reliance on,
 information disseminated through SENS.